Trelegy denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for trelegy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Trelegy Ellipta as Duplicate Therapy

Trelegy Ellipta is a single-inhaler triple therapy combining an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) for COPD or asthma. Cigna may issue a duplicate-therapy denial when its pharmacy system detects that you are simultaneously filling one or more of the individual component classes — for example, a separate LABA/ICS combination inhaler or a standalone LAMA — alongside Trelegy. The system flags this as therapeutic overlap.

This denial is often a pharmacy-system artifact rather than a genuine clinical judgment.

## Why This Denial Is Appealable

Duplicate-therapy flags are frequently generated automatically and do not account for the clinical transition plan your prescriber has in place. If you are in the process of switching from a prior regimen to Trelegy, or if overlapping fills occurred during a transition window, the denial is based on an administrative snapshot rather than ongoing concurrent use. Under ACA §2719 and ERISA §503, you have full internal-appeal and external-review rights.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial; a brief prescriber letter clarifying the transition or the clinical rationale for the regimen is often sufficient.
• External review: Available after internal exhaustion; the IRO must evaluate the clinical appropriateness independently.
• Expedited option: Request if you are without COPD or asthma controller medication and your health is at risk.

## Documentation to Gather

1. Prescriber transition letter — a letter from the treating physician explaining that the overlapping fill was a brief transition (with dates) and that Trelegy is now the sole intended controller regimen, or explaining why concurrent use is clinically appropriate. 2. Medication reconciliation — a current medication list from the prescriber confirming which prior inhalers have been or will be discontinued. 3. Diagnosis and severity documentation — pulmonology or primary care notes confirming the COPD or asthma diagnosis, severity classification, and the clinical rationale for choosing single-inhaler triple therapy. 4. Fill-date records — pharmacy records showing the exact fill dates of the overlapping prescriptions to demonstrate the transition timeline. 5. Applicable guideline reference — reference to the relevant guideline organization (e.g., GOLD guidelines for COPD, GINA for asthma) supporting single-inhaler triple therapy for your disease stage.

## Criteria-Mapping Structure

Address each element of Cigna's duplicate-therapy policy:

| Duplicate-Therapy Criterion | Your Response | |---|---| | Concurrent active fills of overlapping classes | Transition dates documented; overlap was time-limited | | Ongoing therapeutic duplication | Current med list confirms Trelegy as sole controller | | Clinical rationale for regimen | Prescriber letter + guideline organization reference |

Review the FDA-approved prescribing information for Trelegy and Cigna's current coverage policy to confirm the specific criteria that apply to your plan and benefit year.